Evidence map›Paper›PMID 29230126›Full record

ReviewOchsner journal2017

Endocrine Therapy for Early Breast Cancer: Updated Review.

Alexander Tremont, Jonathan Lu, John T Cole

Open access · greenAbstract readReview
PubMed Full text at PMC
In one paragraph

Review in Ochsner journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 4 pooled it
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 4 syntheses or guidelines pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. In Vitro Anti-Cancer Effects ofJournal of evidence-based integrative medicine
    Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Virtual screening,Toxicology reports · 2025
    Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Alexander TremontDepartment of Internal Medicine, Ochsner Clinic Foundation, New Orleans, LA.
Jonathan LuDepartment of Hematology and Oncology, Ochsner Clinic Foundation, New Orleans, LA.
John T ColeDepartment of Hematology and Oncology, Ochsner Clinic Foundation, New Orleans, LA.
Ochsner Medical Center · USThe University of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough breast cancer is still the second most common cause of cancer-related deaths, breast cancer mortality has been declining because of advances in the use of adjuvant therapies.

methodsWe summarize clinical trials involving endocrine therapies used to treat early breast cancer and discuss their inception and recent advances.

resultsEndocrine therapies such as tamoxifen have revolutionized the treatment of breast cancer, resulting in significant decreases in cancer-related mortality. Aromatase inhibitors such as anastrozole and letrozole have further improved breast cancer survival.

conclusionWith the implementation of such therapies resulting in decreased mortality, patients with breast cancer are living longer than ever before. The focus of research is now directed toward the length of treatment and prediction models for recurrence.

Indexed as

Aromatase inhibitorsbreast cancerestrogen receptor antagoniststamoxifen

Identifiers

PMID29230126
PMCPMC5718454
OpenAlexW2766646724

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.